Early Access — free while we kick the tires
EdgarHawk

PTCT PTC THERAPEUTICS, INC. Insider Trading

Latest: CEO Sold $917K of Shares · May 2026
1 filing analyzed · Latest 2026-05-15
Insider buys
0
Insider sells
1
Unique insiders
1
Direction
Net selling
May 2026
2026-05-15
medium
Klein Matthew B. Sell
CHIEF EXECUTIVE OFFICER
12,572 shares
$917,154
@ $72.95
Significance 4/10

Klein (CEO) sells 12,572 shares for $917,153.54 via 4 transactions; pre-arranged 10b5-1 plan.

Klein, as CEO of PTCT, executed 4 separate sales totaling 12,572 shares for $917,153.54 on 2026-05-13 and 2026-05-14, reducing his holdings from 406,570 shares to 393,998 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled and not discretionary. At the current price of $71.47, the stock is -18.3% from its 52-week high of $87.50 and has declined -2.8% over the past 30 days. The company reported revenue of $272,551,000.00 in its latest quarter with net income of -$2,809,000.00 and annual revenue growth of +114.5%, offsetting concerns about current profitability. The scheduled nature of these sales limits inference about Klein's current sentiment; investors should note the filing occurs as a matter of plan mechanics rather than active market timing decision.

More Chemicals and Allied Products companies

Get alerts for PTCT

Add PTCT to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access